Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Annika Öhrfelt

 

 

 

 

 

 

 

 

 

Annika Öhrfelt, Ph.D
E-mail: Annika.Ohrfelt@neuro.gu.se
Tel (office): +46 31 343 24 06

CURRICULUM VITAE


 

 

CURRENT POSITION


Full-time Tenure Senior Research Position (scholarship from Swedish Brain Power consortium), at the research team on “Neurochemical Pathogenesis and Diagnostics” at the Dept. of Neuroscience and Physiologi, University of Gothenburg, Sweden.

EDUCATION AND SCIENTIFIC MERITS


Doctor in Medical Science (PhD), Göteborg University 2004
Master degree in biochemistry (MSc) 1999
Research school of Biomedical Science, Göteborg University 1999
Medical and biomedical studies, Griffith University, Brisbane, Australia 1997
Laboratory engineer, AstraZeneca R&D, Mölndal 1996-1997

RESEARCH INTEREST


The major research interests are:
• Studies on cerebrospinal fluid biochemical markers the clinical diagnosis of AD and other brain disorders, including methodological aspects of cerebrospinal fluid analyses.
• Immunoassays

SCIENTIFIC PRODUCTION


Publications
• About 20 publications (original research papers in peer-reviewed journals).

Selected publictaions (see also under Publications for the research team)

 • Sara Hall*, Annika Öhrfelt*, Radu Constantinescu, Ulf Andreasson, Yulia Surova, Fredrik Bostrom, Christer Nilsson, Håkan Widner, Hilde Decraemer, Katarina Nägga, Lennart Minthon, Elisabet Londos, Eugeen Vanmechelen, Björn Holmberg, Henrik Zetterberg, Kaj Blennow, Oskar Hansson (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders, Archives of Neurology, published online August 27.
*Drs Hall and Öhrfelt contributed equally to the present work.

 

Annika Öhrfelt, Henrik Zetterberg, Kerstin Andersson, Rita Persson, Dzemila Secic, Gunnar Brinkmalm, Anders Wallin, Ezra Mulugeta, Paul T. Francis, Eugeen Vanmechelen, Dag Aarsland, Clive Ballard, Kaj Blennow, Ann Westman-Brinkmalm (2011) Identification of novel -synuclein isoforms in human brain tissue by using an online nano-LC-ESI-FTICR-MS method. Neurochemical Research, 36 (11), 2029-42.

Annika Öhrfelt, Ulf Andreasson, Adam Simon, Henrik Zetterberg, Åke Edman, William Potter, Daniel Holder, Viswanath Devanarayan, Jeffrey Seeburger, A. David Smith, Kaj Blennow, Anders Wallin (2011) Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease, EXTRA Dementia and Geriatric Cognitive Disorders 1: 31-42.

Annika Öhrfelt, Pierre Grognet, Niels Andreasen, Anders Wallin, Eugeen Vanmechelen, Kaj Blennow, Henrik Zetterberg (2009) Cerebrospinal fluid α-synuclein in neurodegenerative disorders – A marker of synapse loss?, Neurosci Lett 450: 332-335.

A Olsson*, H Vanderstichele, N Andreasen, G De Meyer, A Wallin, B Holmberg, L Rosengren, E Vanmechelen, K Blennow, (2005) Simultaneous measurement of A(1-42), total tau and phosphorylated tau (Thr 181) in cerebrospinal fluid using the xMAPTM technology, Clin Chem, Feb;51(2), 336-345.
*Please note the change in surname from Olsson to Öhrfelt.

 

 

SCIENTIFIC AWARDS


• In 2004, my PhD thesis was selected as one of the best clinical dissertations by the medical experts at the journal “Incitament”.

MEMBERSHIPS


The Swedish Society of Medicine

 

CONGRESSES

 

 

Invited speaker

• Biomarkers in clinical trials of dementia, “The 2nd International Winter-Conference on Alzheimer’s Disease”, Zürs, Austria, Österrike, 9-12 December 2005.

 

Oral presentation

• Development of a novel ELISA for quantification of SNAP-25 in human brain tissue and cerebrospinal fluid, Swedish Brain Power Workshop VIII, Sånga-Säby, Sweden, 27-28 September 2012.

• Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients, “The 8th International Conference on Alzheimer´s Disease and Related Disorders”, Stockholm, Sweden, 20-25 July 2002.

Poster presentations

• Development of a novel ELISA for quantification of SNAP-25 in human brain tissue and cerebrospinal fluid, 11th International Conference AD/PD, Florence, Italy, 6-10 March 2013.

• Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease, Vas-Cog, Lille, France, 11-14 September, 2011.

• Evaluation of 89 analytes as biomarkers for Alzheimer’s disease, vascular dementia and as predictors in mild cognitive impairment, “Swedish Brain Power meeting work shop”, Bålsta, Sweden, 25-26 September, 2008.

• Simultaneous measurement of Aß(1-42), tau, phosphorylated tau in cerebrospinal fluid using the xMAPTM technology, “The 9th International Conference on Alzheimer’s Disease and Related Disorders”, Philadelphia, USA, 17-22 July 2004.

• Marked increase of ß-amyloid(1-42) in ventricular cerebrospinal fluid after severe traumatic brain injury, “The 6th International conference on progress in Alzheimer´s and Parkinson´s Disease”, Seville, Spain, 8-12 May 2003.

• Unaltered plasma levels of ß-amyloid (Aß42) upon stimulation of human platelets, “The 5th International conference on progress in Alzheimer´s and Parkinson´s disease”, Kyoto, Japan, 31 March-5 April 2001.

 

Sidansvarig: Staffan Persson|Sidan uppdaterades: 2013-04-02
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?